NDAORALTABLET, EXTENDED RELEASE
Approved
Jan 2003
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
5/8 — Partial
XANAX XR (alprazolam) by Viatris (2) is 1,4 benzodiazepine. Approved for panic disorder, generalized anxiety disorder, anxiety disorders and 1 more indications. First approved in 2003.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
XANAX XR (alprazolam) is an extended-release benzodiazepine that enhances GABA-mediated synaptic inhibition by binding to GABAA receptors in the brain. It is indicated for generalized anxiety disorder, panic disorder, and anxiety disorders. The drug provides sustained symptom relief over 12+ hours due to its extended-release formulation and 11.2-hour half-life.
$0.295MPart D
LOE ApproachingDeclining
Product approaching loss of exclusivity with minimal Part D claims signals declining team investment and likely consolidation within anxiety/panic portfolio.
Mechanism of Action
1,4 benzodiazepine. Alprazolam exerts its effect for the acute treatment of generalized anxiety disorder and panic disorder through binding to the benzodiazepine site of gamma-aminobutyric acid-A (GABAA) receptors in the brain and enhances GABA-mediated synaptic inhibition. 12.3 Pharmacokinetics…
Worked on XANAX XR at Viatris (2)? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.